ERBB2 and neoplasm: HER2 is overexpressed in a high percentage of breast cancer (25–30%) and its overexpression is associated with aggressive tumours, a high rate of metastasis and relapse, poor prognosis, and limitation in treatment (in most cases it became resistant to endocrine therapy such as tamoxifen) [93, 94].